Skip to main content
. 2020 Aug 18;8(8):1250. doi: 10.3390/microorganisms8081250

Figure 3.

Figure 3

De novo drug discovery versus drug repurposing. The time required from hit identification to lead optimization (upper panel) is saved in drug repurposing (lower panel). In the case of SARS-CoV-2 3CLpro, virtual screening, biochemical, and cell-based assays were applied to identify protease inhibitors from FDA-approved drugs. The duration required in individual processes is based on [59], which gives detailed information for drug repurposing. It is worth mentioning that the timeline for COVID-19 might be different from other diseases due to its pandemic status. HTS, high throughput screening. FDA, the Food and Drug Administration.